Tenpoint Therapeutics and Visus Therapeutics Complete Merger to Advance Ophthalmic Pipeline

Visiox Pharmaceuticals Announces Definitive Merger With Ocuvex Therapeutics

August 19, 2024

Healthcare Services

Visiox Pharmaceuticals, Inc. entered into a definitive merger agreement with Ocuvex Therapeutics, Inc., an ophthalmic pharmaceutical company focused on developing and commercializing therapies for glaucoma and other eye disorders. The combined company will operate under the Ocuvex name, aiming to strengthen its ophthalmic portfolio and accelerate commercialization of near-term products.

Lupin to Acquire VISUfarma from GHO Capital

September 29, 2025

Pharmaceuticals

Lupin Limited, through its wholly owned subsidiary Nanomi B.V., has signed a definitive agreement to acquire VISUfarma B.V., a pan-European ophthalmology specialty pharmaceutical business. The deal is expected to close by the end of 2025, subject to customary closing conditions, and will expand Lupin’s specialty ophthalmology presence across major European markets.

Hilco Vision Acquires Bruder Healthcare

September 17, 2021

Medical Devices

Hilco Vision, a portfolio company of Windjammer Capital Investors, has acquired Bruder Healthcare effective September 17, 2021; terms were not disclosed. Bruder, a maker of therapeutic and ophthalmic dry-eye products based in Alpharetta, Georgia, will be integrated into Hilco’s product portfolio as the transaction represents a PE-backed add-on to expand Hilco’s offerings to eye care professionals and consumers.

Ares Management Acquires Majority Stake in Point Vision; Bpifrance Takes Minority Stake

October 12, 2021

Healthcare Services

Funds managed by the Private Equity Group of Ares Management acquired a majority stake in Point Vision, the French network of ophthalmology centers, while Bpifrance took a minority stake. The founders and key professionals are reinvesting as Point Vision plans to continue rolling out new centers across France and expand its services including teleconsultation and additional surgical specialties.

Vistagen Acquires Pherin Pharmaceuticals

December 21, 2022

Biotechnology

Vistagen (Nasdaq: VTGN) will acquire Pherin Pharmaceuticals in an all-stock transaction (approximately 12.4 million shares plus nominal cash), giving Vistagen full ownership of Pherin's pherine drug pipeline and intellectual property. The deal eliminates future royalty and milestone obligations related to PH94B and PH10 and adds three early-stage pherine candidates to Vistagen's development portfolio.

BVI Acquires Benz Research & Development and SpecialEyes

October 15, 2020

Medical Devices

BVI, a PE-backed global ophthalmic medical device company, has acquired Benz Research & Development and its customized contact lens subsidiary SpecialEyes, both based in Sarasota, Florida. The deal expands BVI's intraocular lens (IOL) materials and contact lens capabilities — leveraging Benz's proprietary molding technology and materials (used in 50+ million implants) to increase IOL production scale and end-to-end capability.